{"id":251796,"date":"2024-02-05T00:00:00","date_gmt":"2024-02-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0044-biopharma-amyotrophic-lateral-sclerosis-epidemiology-2\/"},"modified":"2026-03-31T10:31:04","modified_gmt":"2026-03-31T10:31:04","slug":"epidcg0044-biopharma-amyotrophic-lateral-sclerosis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0044-biopharma-amyotrophic-lateral-sclerosis-epidemiology-mature-markets\/","title":{"rendered":"Amyotrophic Lateral Sclerosis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of amyotrophic lateral sclerosis (<abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 15 <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of (definite+probable+possible) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of (definite) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of (probable) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of (possible) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of (definite+probable+possible) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of (definite) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of (probable) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of (possible) <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of familial <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of sporadic <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> with Alzheimer\u2019s disease.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> with dementia.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> with epilepsy.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> with frontotemporal dementia.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"amyotrophic lateral sclerosis\">ALS<\/abbr> with Parkinson\u2019s disease.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251796","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-amyotrophic-lateral-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251796\/revisions"}],"predecessor-version":[{"id":281177,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251796\/revisions\/281177"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}